Related Experiment Video
Updated: Dec 13, 2025
Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography
Published on: January 27, 2023
Patent Ductus Arteriosus-Time for a Definitive Trial
Souvik Mitra1, Patrick J McNamara2
1Department of Pediatrics, Dalhousie University, G-2214, 5850/5980 University Avenue, Halifax, Nova Scotia B3K 6R8, Canada; Department of Community Health & Epidemiology, Dalhousie University, G-2214, 5850/5980 University Avenue, Halifax, Nova Scotia B3K 6R8, Canada. Electronic address: https://twitter.com/souvik_neo.
Insights
Treating patent ductus arteriosus (PDA) in preterm infants remains uncertain. Current evidence is limited by trial design flaws, impacting clinical outcome understanding and treatment decisions.
Area of Science:
- Neonatal Medicine
- Pediatric Cardiology
- Clinical Trials
Background:
- Over 70 randomized controlled trials (RCTs) exist for managing patent ductus arteriosus (PDA) in preterm infants.
- Clinical uncertainty persists regarding whether PDA treatment improves significant patient outcomes.
- Previous trials focused on pharmacologic closure but had design limitations (older infants, varied definitions, open-label).
Purpose of the Study:
- To evaluate the impact of current evidence on clinical decision-making for PDA management in preterm infants.
- To identify limitations in existing RCTs that hinder definitive conclusions on PDA treatment efficacy.
- To address the growing consideration of 'no treatment' as a viable option regardless of infant and PDA characteristics.
Main Methods:
- Systematic review of over 70 randomized controlled trials on PDA management in preterm infants.
- Analysis of trial designs, including participant age, PDA definitions, and treatment blinding.
- Assessment of the influence of trial methodologies on the interpretation of clinical outcomes.
Main Results:
- Existing RCTs on PDA management in preterm infants exhibit significant design flaws.
- Varied PDA definitions and open-label treatments in older trials complicate outcome interpretation.
- Methodological limitations may contribute to uncertainty about the benefits of PDA treatment.
Conclusions:
- Current evidence on PDA management in preterm infants is insufficient to guide clinical practice definitively.
- Limitations in past research hinder the ability to ascertain the clinical benefits of PDA treatment.
- Further well-designed trials are needed to clarify the optimal management strategy for PDA in this population.
Abstract:
More than 70 randomized controlled trials have been conducted on the management of patent ductus arteriosus (PDA) in preterm infants. Yet, clinicians are unsure if treating a PDA improves clinically important outcomes. Earlier clinical trials have primarily explored which pharmacotherapeutic agent effectively closes the PDA. Because many of these trials included older infants, had widely varying PDA definitions, and provided open-label treatment, it is difficult to draw inferences on clinical outcomes based on the results of these trials. These flaws in trial design might have contributed to the growing notion that "no treatment" is a feasible option irrespective of the clinical characteristics of the infant and the PDA shunt volume.
